Jagsonpal Pharmaceuticals Ltd. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 756.1M
Gross Profit 486.8M 64.39%
Operating Income 118.6M 15.69%
Net Income 108.0M 14.28%
EPS (Diluted) ₹1.58

Balance Sheet Metrics

Total Assets 2.8B
Total Liabilities 383.1M
Shareholders Equity 2.4B
Debt to Equity 0.16

Cash Flow Metrics

Revenue & Profitability Trend

Jagsonpal Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i2.7B2.1B2.4B2.2B1.9B
Cost of Goods Sold i964.4M801.3M925.1M892.8M809.3M
Gross Profit i1.7B1.3B1.4B1.3B1.1B
Gross Margin % i64.1%61.6%60.9%59.0%56.9%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i-201.4M234.7M240.5M172.6M
Other Operating Expenses i502.7M223.0M185.6M180.3M136.3M
Total Operating Expenses i502.7M424.4M420.3M420.8M308.9M
Operating Income i429.4M216.7M343.3M245.4M187.9M
Operating Margin % i16.0%10.4%14.5%11.3%10.0%
Non-Operating Items
Interest Income i-85.9M34.3M15.5M29.9M
Interest Expense i9.6M7.8M2.8M2.6M4.3M
Other Non-Operating Income-----
Pre-tax Income i698.6M298.7M348.1M266.4M218.7M
Income Tax i145.0M74.1M80.9M77.9M48.1M
Effective Tax Rate % i20.8%24.8%23.2%29.2%22.0%
Net Income i553.6M224.6M267.2M188.6M170.6M
Net Margin % i20.6%10.8%11.3%8.7%9.1%
Key Metrics
EBITDA i592.6M323.1M392.1M289.0M231.4M
EPS (Basic) i₹8.26₹3.40₹4.08₹2.88₹2.60
EPS (Diluted) i₹8.22₹3.38₹4.08₹2.88₹2.60
Basic Shares Outstanding i6702312366123627654950006549500065495000
Diluted Shares Outstanding i6702312366123627654950006549500065495000

Income Statement Trend

Jagsonpal Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i112.2M127.6M110.5M225.3M589.4M
Short-term Investments i1.2B1.4B1.0B248.8M52.3M
Accounts Receivable i131.8M109.5M208.7M155.8M126.6M
Inventory i152.0M150.0M206.8M297.4M297.2M
Other Current Assets40.2M80.8M80.7M-81.0K120.6M
Total Current Assets i1.6B2.0B1.6B1.1B1.2B
Non-Current Assets
Property, Plant & Equipment i88.4M83.9M59.3M223.7M233.5M
Goodwill i953.1M-0600.0K600.0K
Intangible Assets i759.2M--23.5M23.5M
Long-term Investments-----
Other Non-Current Assets44.2M21.1M20.3M29.2M8.4M
Total Non-Current Assets i1.2B178.2M303.9M551.4M461.9M
Total Assets i2.8B2.2B1.9B1.6B1.6B
Liabilities
Current Liabilities
Accounts Payable i97.3M76.0M165.8M185.5M206.8M
Short-term Debt i16.1M13.8M7.5M067.9M
Current Portion of Long-term Debt-----
Other Current Liabilities32.0M1.0M1.4M230.0K44.3M
Total Current Liabilities i259.0M191.3M275.7M269.7M375.8M
Non-Current Liabilities
Long-term Debt i76.3M75.6M52.5M00
Deferred Tax Liabilities i30.7M20.7M21.6M32.4M23.4M
Other Non-Current Liabilities-----
Total Non-Current Liabilities i124.1M105.5M84.8M44.9M23.5M
Total Liabilities i383.1M296.8M360.6M314.7M399.4M
Equity
Common Stock i132.8M132.2M131.0M131.0M131.0M
Retained Earnings i-1.0B945.4M693.7M585.9M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i2.4B1.9B1.6B1.3B1.2B
Key Metrics
Total Debt i92.4M89.4M60.0M067.9M
Working Capital i1.4B1.8B1.4B821.1M810.4M

Balance Sheet Composition

Jagsonpal Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i698.6M298.7M348.1M266.4M218.7M
Depreciation & Amortization i-----
Stock-Based Compensation i68.0M133.1M87.6M0-
Working Capital Changes i30.0M143.0M117.5M-97.3M136.8M
Operating Cash Flow i532.9M497.0M550.9M156.5M333.6M
Investing Activities
Capital Expenditures i353.7M-2.5M9.8M-4.7M-4.7M
Acquisitions i-936.6M----
Investment Purchases i-2.6B-1.4B-1.1B-284.5M-41.7M
Investment Sales i2.6B1.0B438.2M--
Investing Cash Flow i-529.9M-319.2M-611.0M-289.2M-46.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-132.3M-131.0M--104.8M-26.2M
Debt Issuance i-----
Debt Repayment i--0-67.9M-
Financing Cash Flow i-98.4M-74.6M-3.2M-240.5M-26.2M
Free Cash Flow i549.5M349.2M463.4M58.6M277.5M
Net Change in Cash i-95.3M103.2M-63.3M-373.2M260.9M

Cash Flow Trend

Jagsonpal Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 27.17
Price to Book 6.86
Price to Sales 5.78
PEG Ratio 0.26

Profitability Ratios

Profit Margin 21.50%
Operating Margin 15.69%
Return on Equity 23.07%
Return on Assets 19.90%

Financial Health

Current Ratio 6.22
Debt to Equity 3.85
Beta 0.24

Per Share Data

EPS (TTM) ₹9.02
Book Value per Share ₹35.72
Revenue per Share ₹42.34

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
jagsnpharm16.4B27.176.8623.07%21.50%3.85
Sun Pharmaceutical 3.9T37.885.4515.08%19.29%3.26
Divi's Laboratories 1.6T70.4210.8814.64%23.89%0.03
Sun Pharma Advanced 45.5B-13.34-21.04157.88%-53.22%-1.24
Aarti Drugs 44.4B23.593.2512.28%7.80%44.92
Sequent Scientific 43.9B154.186.242.84%1.85%62.47

Financial data is updated regularly. All figures are in the company's reporting currency.